Helus Pharma Q1 FY2027: $47.8M Net Loss, $166.4M Cash, Phase 3 Data on Track for Q4

summarizeSummary

Helus Pharma reported a $47.8M quarterly net loss with $166.4M in cash, while confirming Phase 3 APPROACH data remains on track for Q4 2026. Subsequent share issuances from RSU vesting and warrant exercises add to the float.

check_boxKey Events · Earnings and Guidance · HELP

• Q1 FY2027 Net Loss of $47.8M

  Net loss nearly doubled from $24.6M a year ago, driven by a $30.8M research spend as the Phase 3 APPROACH trial neared completion.

• Cash Position of $166.4M

  Cash at June 30, 2026 was $166.4M, with operating cash outflow of $37.1M for the quarter — implying roughly 4-5 quarters of runway at current burn.

• Phase 3 APPROACH Data on Track for Q4 2026

  Enrollment completed with 223 participants; topline efficacy data readout remains expected in Q4 2026.

• Post-Quarter Share Issuances Expand Float

  7,889,846 shares issued on RSU vesting July 1, 2026, and 2,997,248 shares issued on pre-funded warrant exercise August 10, 2026 — a combined ~15% increase to shares outstanding.

auto_awesomeAnalysis · HELP · Life Sciences

Helus Pharma's first-quarter fiscal 2027 results show a net loss of $47.8 million, nearly double the prior-year loss, driven by a surge in research spending as the company pushes its Phase 3 APPROACH trial toward a Q4 2026 data readout. Cash of $166.4 million provides runway, but the burn rate of $37.1 million per quarter means the company will likely need additional capital before commercialization. The filing also reveals significant share issuance after quarter-end — 7.9 million shares from RSU vesting and 3.0 million from pre-funded warrant exercises — which expands the float and could pressure the stock near its 52-week high.